‘Phar­ma Bro’ Mar­tin Shkre­li's com­pa­nies file for bank­rupt­cy

The com­pa­ny found­ed by Mar­tin Shkre­li, the “Phar­ma Bro” known for hik­ing the price of an old drug by 4,000%, has filed for Chap­ter 11 bank­rupt­cy in Delaware.

Vy­era Phar­ma­ceu­ti­cals, which is the re­brand­ed ver­sion of Shkre­li’s Tur­ing Phar­ma­ceu­ti­cals, its par­ent com­pa­ny Phoenixus AG and four oth­er com­pa­nies filed for Chap­ter 11 pro­tec­tion on Wednes­day, ac­cord­ing to doc­u­ments from the US Bank­rupt­cy Court for the Dis­trict of Delaware. The case fil­ing for Vy­era states that the phar­ma plans to have a sale or liq­ui­da­tion of the “liq­ui­dat­ing debtors” and for Phoenixus to be pre­served.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER